Latest filing published 07 Aug 2026 for Jazz Pharmaceuticals plc. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Jennifer E. Cook (board member) discloses dealings in 3 companies, chiefly BridgeBio Pharma, Inc., Jazz Pharmaceuticals plc and Denali Therapeutics Inc. The record holds 33 filings, for trades running from 1 June 2021 to 5 August 2026.
Every open-market trade on record is a sale: 10 sales worth €11.7M. The totals exclude 4 filings filed without an amount. The rest of the record consists of 14 share grants and 9 option exercises. So far in 2026, the count stands at no purchases and 6 sales.
On 7 August 2026 came the latest disclosure, a share grant in Jazz Pharmaceuticals plc. Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 33 declarations